Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | USP4 | Q13107 | 1/20 | 0.38 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666165 | 0.81 | PYCR1 (0.47) | LOXL2PYCR1USP4USP7HDAC8 | |
| SCHEMBL2504209 | 0.80 | KDM4E (0.68) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| SCHEMBL509578 | 0.79 | LOXL2 (1.00) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| SCHEMBL578421 | 0.78 | PYCR1 (0.46) | LOXL2PYCR1USP4USP7HDAC8 | |
| SCHEMBL3840593 | 0.78 | HDAC8 (0.43) | LOXL2CYP3A4HDAC8CYP2A6ALDH1A1 | |
| SCHEMBL7284285 | 0.77 | LOXL2 (0.65) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| Hydrochloric Acid SCHEMBL8135282 | 0.77 | LOXL2 (0.95) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| Hydrochloric Acid SCHEMBL30925271 | 0.77 | KDM4E (0.74) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| SCHEMBL13671292 | 0.77 | LOXL2 (0.39) | LOXL2CYP3A4PYCR1USP4USP7 | |
| SCHEMBL12085987 | 0.77 | LOXL2 (0.39) | LOXL2KDM4EPYCR1USP4USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| CN-118515621-A | Azolyl alcohol compound containing ethynyl and application thereof | 沈阳药科大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-117794924-A | Compounds useful as inhibitors of ATR kinase | 苏州爱科百发生物医药技术有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024064080-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-3915989-B1 | JAK INHIBITOR AND PREPARATION METHOD THEREFOR | FELICAMED BIOTECHNOLOGY CO LTD (CN) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023016525-A1 | COMPOUND AS ATR KINASE INHIBITOR | 苏州爱科百发生物医药技术有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016525-A1 | COMPOUND AS ATR KINASE INHIBITOR | 苏州爱科百发生物医药技术有限公司 | 2023-02-16 | — | — | WO | disclosed |
| EP-3798214-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3770148-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-27 | — | — | EP | disclosed |
| US-9533965-B2 | 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-01-03 | — | — | US | disclosed |
| US-20160347748-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | ONCOTARTIS INC. | 2016-12-01 | — | — | US | disclosed |
| EP-2813495-B1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2016-09-28 | — | — | EP | disclosed |
| EP-2813495-B1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2016-09-28 | — | — | EP | disclosed |
| EP-2813495-A1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813495-A1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-12-17 | — | — | EP | disclosed |
| EP-2359862-B1 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-7473797-B2 | Methods of 1,3-enyne preparation using copper (I) catalysts | UNIVERSITY OF MASSACHUSETTS (US) | 2009-01-06 | — | — | US | disclosed |
| US-20050255575-A1 | Methods of 1,3-enyne preparation using copper (I) catalysts | NATIONAL SCIENCE FOUNDATION | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | ATR, CHEK2, CHEK1 | LOXL2 3717/4885KDM4E 2567/4885CYP3A4 3039/4885 |
| US-20160347748-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | NAMPT, NNT, NADK | LOXL2 2767/4885KDM4E 1324/4885CYP3A4 1293/4885 |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | LOXL2 2009/4885KDM4E 3486/4885CYP3A4 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.